Regulation of systemic tissue injury by coagulation inhibitors in B6.MRL/lpr autoimmune mice

C. Moratz*, R. Robbins, J. Eickhoff, J. Edison, H. Lui, S. Peng

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Impaired fibrinolysis and complement activation in Systemic Lupus Erythematosus contributes to disease amplification including increased risk of thrombosis and tissue Ischemia/Reperfusion (IR) injury. Previous work has demonstrated complement is a key regulator of tissue injury. In these studies inhibitors had varying efficacies in attenuating injury at primary versus systemic sites, such as lung. In this study the role of coagulation factors in tissue injury and complement function was evaluated. Tissue Factor Pathway Inhibitor (TFPI), an extrinsic pathway inhibitor, and Anti-Thrombin III, the downstream common pathway inhibitor, were utilized in this study. TFPI was more effective in attenuated primary intestinal tissue injury. However both attenuated systemic lung injury. However, ATIII treatment resulting in enhanced degradation of C3 split products in lung tissue compared to TFPI. This work delineates the influence of specific early and late coagulation pathway components during initial tissue injury versus later distal systemic tissue injury mechanism.

Original languageEnglish
Pages (from-to)169-178
Number of pages10
JournalClinical Immunology
StatePublished - Dec 2018


  • Coagulation inhibition
  • Complement
  • Systemic lupus erythematosus
  • Tissue injury


Dive into the research topics of 'Regulation of systemic tissue injury by coagulation inhibitors in B6.MRL/lpr autoimmune mice'. Together they form a unique fingerprint.

Cite this